Emergent BioSolutions Inc 2023 SR
The report highlights Emergent BioSolutions' 2023 achievements, including the FDA approval and over-the-counter launch of NARCAN® Nasal Spray and the approval of CYFENDUS® anthrax vaccine. The company conducted a new materiality assessment and reinforced its ESG governance by creating a dedicated ESG management role. Environmental efforts focused on calculating Scope 1 and 2 emissions and identifying energy conservation measures at manufacturing sites. Social initiatives emphasized patient safety, clinical trial integrity, and employee well-being, while corporate governance focused on a 'Speak Up' culture and maturing ethics and compliance programs.
Company: Emergent BioSolutions Inc
Sector: Manufacturing
Country: United States
Year: 2023
Type: SR
Pages: 49
Emergent BioSolutions Inc
The report highlights Emergent BioSolutions' 2023 achievements, including the FDA approval and over-the-counter launch of NARCAN® Nasal Spray and the approval of CYFENDUS® anthrax vaccine. The company conducted a new materiality assessment and reinforced its ESG governance by creating a dedicated ESG management role. Environmental efforts focused on calculating Scope 1 and 2 emissions and identifying energy conservation measures at manufacturing sites. Social initiatives emphasized patient safety, clinical trial integrity, and employee well-being, while corporate governance focused on a 'Speak Up' culture and maturing ethics and compliance programs.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Published
Apr 29, 2024
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Sustainable Development Goals
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Water Consumption
Women on Board
Workplace Fatalities
Employees